Human Genome Sciences (HGSI)

:)

Following Ultralong

going down!

Given the dearth of success in attacking Lupus, and the promise of HGSI's Benlysta, the sky is truly the limit for this company. Additionally, the road that HGSI has followed to achieve this milestone is replicable for other, similar, autoimmune diseases and could provide an enticing pipeline for a large pharma takeover.

DEFINE TAKEOVER

stock that has shot up alot in past year yet are in CAPs.

Still crap

Beyond the expectation that GSK will make an offer on HGSI late 2Q or early 3Q, 3 billion in potential goes a long way towards this company beating the street and Benylsta isn't the only pony in the stable.

Huge run up after test results. Wait for it to correct and rebuy after 20%. Same thing happened after the last positive test results.

HGSI has a too high valuation compared to its sales potential. It is also loss making at least until 2010.

Totally over-rated drug for MS. 43% of patients improved on their so-called HOT MS drug vs. 33% improving on placebo.
NOT impressive. Company's Anthrax drug just bombed.
Stock overvalued.

In good financial times speculative biotech companies have time and money to develop the next block buster drug. With the health care changes and financial uncertainty these biotech companies won't be given much time to prove themselves.

This is a great longterm buy. Wait till the full value of this company is realized. Plus it might have some other great trial results! This stock will easily return 50% in a year. A great/ reasonably safe buy

Testing Schaeffer on a short

I feel confident HGSI will soon conclude another successful Phase III trial and consequently will receive FDA approval to bring their drug for Lupus to market. Once that happens the stock will take off to new highs.
.

The pharmaceutical company Human Genome Sciences has consistently been coming out with groundbreaking medicines and cures for dangerous diseases. Their stock went from around $0.85 to $20 in just a few months with the release of one drug. They have many more in late stage development and some others almost in production. I think that HGSI will continue to rise with the production of more new medicines. This is a good pick for the future.

Even if the company can get its drug to market, the market for these drugs is small and the government efforts to control costs will also limit the potential profits of these small drug companies.

The company has three late-stage products sure to become great earnings producers. The current progress of its Lupus medication alone holds great potential, even against competitor advances.

lupus drug